MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Epirus Biopharmaceuticals Company Profile (NASDAQ:EPRS)

Consensus Ratings for Epirus Biopharmaceuticals (NASDAQ:EPRS) (?)
Ratings Breakdown: 3 Hold Rating(s)
Consensus Rating:Hold (Score: 2.00)
Consensus Price Target: $7.33 (1,310.26% upside)

Analysts' Ratings History for Epirus Biopharmaceuticals (NASDAQ:EPRS)
Show:
DateFirmActionRatingPrice TargetActions
5/15/2016Leerink SwannDowngradeOutperform -> Market PerformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/11/2016BTIG ResearchDowngradeBuy -> NeutralView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/11/2016WedbushDowngradeOutperform -> Neutral$11.00 -> $2.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 6/27/2014 forward)
Earnings History for Epirus Biopharmaceuticals (NASDAQ:EPRS)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
5/13/2016        
3/15/2016Q415($0.56)($0.63)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/16/2015Q315($0.51)($0.59)$221.00 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/7/2015Q215($0.38)($0.65)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/12/2015Q1($0.43)($0.39)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/23/2015Q414($0.99)($0.80)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/10/2014($0.43)($1.28)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/20/2014($1.20)($1.52)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/9/2014Q114$0.20($0.15)$9.00 million$1.60 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/13/2014($0.14)($0.29)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/4/2013Q313($0.50)($0.46)$3.66 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/1/2013Q2 2013($0.07)($0.08)$2.91 million$3.89 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/2/2013Q1 2013($0.07)($0.06)$3.44 million$3.70 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/6/2013Q4 2012($0.08)($0.06)$3.12 million$3.67 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)
Earnings Estimates for Epirus Biopharmaceuticals (NASDAQ:EPRS)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20162($0.66)($0.40)($0.53)
Q2 20162($0.52)($0.26)($0.39)
Q3 20162($0.43)($0.16)($0.30)
Q4 20162($0.27)($0.15)($0.21)
Q1 20171($0.16)($0.16)($0.16)
Q2 20171($0.12)($0.12)($0.12)
Q3 20171($0.11)($0.11)($0.11)
Q4 20171($0.11)($0.11)($0.11)
(Data provided by Zacks Investment Research)
Dividend History for Epirus Biopharmaceuticals (NASDAQ:EPRS)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for Epirus Biopharmaceuticals (NASDAQ:EPRS)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
12/21/2015Robert TicktinGeneral CounselBuy3,000$3.72$11,160.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/17/2015Aurentz VincentInsiderBuy2,200$3.43$7,546.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/16/2015Amit MunshiCEOBuy8,270$2.80$23,156.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/15/2015Amit MunshiCEOBuy8,069$2.87$23,158.03View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/9/2015Amit MunshiCEOBuy13,190$4.07$53,683.30View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/9/2015Aurentz VincentInsiderBuy2,800$3.85$10,780.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/21/2015Amit MunshiCEOBuy10,000$6.19$61,900.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/18/2015Amit MunshiCEOBuy10,000$5.99$59,900.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/6/2015Montreux Equity Partners Iv LpMajor ShareholderSell167,316$5.00$836,580.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/4/2015Montreux Equity Partners Iv LpMajor ShareholderSell52,684$4.98$262,366.32View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/4/2015Scott M RocklageDirectorBuy400,000$5.00$2,000,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/26/2015Montreux Equity Partners Iv LpMajor ShareholderSell38,516$6.47$249,198.52View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/23/2015Montreux Equity Partners Iv LpMajor ShareholderSell22,530$6.29$141,713.70View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)
Latest Headlines for Epirus Biopharmaceuticals (NASDAQ:EPRS)
DateHeadline
06/24/16 03:56 PMHC Stocks Alerts: Gilead Sciences, Inc. (NASDAQ:GILD), Epirus Biopharmaceuticals Inc (NASDAQ:EPRS) - share market updates (press release)
06/24/16 03:56 PMEPIRUS Biopharmaceuticals, Inc. (NASDAQ:EPRS) Earnings Glance and Target Price Review - Engelwood Daily
06/24/16 10:40 AMCovering the Bases on EPIRUS Biopharmaceuticals, Inc. (NASDAQ:EPRS): Where is the Stock Going? - Press Telegraph
06/24/16 10:40 AMAnalysts Observing Trading Stocks: EPIRUS Biopharmaceuticals, Inc. (NASDAQ:EPRS) , Baxter International Inc ... - Street Updates
06/21/16 03:38 PMHealthcare Bears: EPIRUS Biopharmaceuticals, Inc. (NASDAQ:EPRS), Innocoll Holdings plc (NASDAQ:INNL), Egalet ... - KC Register
06/21/16 11:57 AMETF’s with exposure to EPIRUS Biopharmaceuticals, Inc. : June 21, 2016 -
06/14/16 03:07 PMEPIRUS BIOPHARMACEUTICALS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events -
06/13/16 06:30 AM[$$] Billions at Stake as Biotech-Copycat Startups Chase Pharma Giants -
06/10/16 06:26 PMETF’s with exposure to EPIRUS Biopharmaceuticals, Inc. : June 10, 2016 -
06/05/16 07:32 AMPerformance report of the company: Epirus Biopharmaceuticals Inc (NASDAQ:EPRS) - News Oracle
06/03/16 04:05 PMAnalyst Recommended Buy These Stocks: VeriFone Systems, Inc. (NYSE:PAY), EPIRUS Biopharmaceuticals, Inc ... - Beacon Chronicle
06/03/16 08:13 AMShare Rating Focus on EPIRUS Biopharmaceuticals, Inc. (NASDAQ:EPRS) - HNN - Share Rating Focus on EPIRUS Biopharmaceuticals, Inc. (NASDAQ:EPRS)HNNPresently, Wall Street analysts have given a consensus stock rating of 2.33 on shares of EPIRUS Biopharmaceuticals, Inc. (NASDAQ:EPRS). Covering analysts will typically provide Buy, Sell, or Hold recommendations based on extensive research.and more »
06/02/16 07:14 AMTarget Price and Stock Performance Rundown for EPIRUS Biopharmaceuticals, Inc. (NASDAQ:EPRS) - HNN - Target Price and Stock Performance Rundown for EPIRUS Biopharmaceuticals, Inc. (NASDAQ:EPRS)HNNDuring the latest trading session, EPIRUS Biopharmaceuticals, Inc. (NASDAQ:EPRS) shares traded +17.72%. Monitoring the stock price relative to moving averages may offer enhanced perspective on stock performance. After a recent check, shares have ...and more »
06/01/16 10:09 PMStock Poised for a Rebound: EPIRUS Biopharmaceuticals, Inc. (NASDAQ:EPRS) - HNN - Stock Poised for a Rebound: EPIRUS Biopharmaceuticals, Inc. (NASDAQ:EPRS)HNNMany investors are considering shares of EPIRUS Biopharmaceuticals, Inc. (NASDAQ:EPRS) to be “oversold” as the commodity reached $0.62 on a recent tick. An oversold stock has a current price that an investor thinks is lower than the inherent value of ...
05/30/16 08:53 PMEPIRUS Biopharmaceuticals, Inc. (EPRS) Broker Price Targets For The Coming Week - Share Trading News - EPIRUS Biopharmaceuticals, Inc. (EPRS) Broker Price Targets For The Coming WeekShare Trading NewsMarket analysts have recently updated their ratings and price targets on shares of EPIRUS Biopharmaceuticals, Inc. (EPRS). The latest reports which are currently in issue on Monday 30th of May state 0 analysts have a rating of “strong buy”, 0 analysts ...How Analysts Rated Epirus Biopharmaceuticals Inc (NASDAQ:EPRS) Last Week?Franklin IndependentPerformance at a Glance on EPIRUS Biopharmaceuticals, Inc. (NASDAQ:EPRS)HNNall 3 news articles »
05/28/16 01:47 PMRecent Movements of Stocks: Bruker Corporation (NASDAQ:BRKR) , EPIRUS Biopharmaceuticals, Inc. (NASDAQ:EPRS) - Street Updates - Recent Movements of Stocks: Bruker Corporation (NASDAQ:BRKR) , EPIRUS Biopharmaceuticals, Inc. (NASDAQ:EPRS)Street UpdatesEPIRUS Biopharmaceuticals, Inc. (NASDAQ:EPRS) moved in red zone with decline of -0.06 points or -9.67% to $0.57. The company has a market worth of $14.92M.Total 658.56 thousand shares were exchanged in last trading session as opposed to average ...and more »
05/26/16 01:53 PMTarget Check and Stock Performance Recap EPIRUS Biopharmaceuticals, Inc. (NASDAQ:EPRS) - Wall Street Hints and News - Target Check and Stock Performance Recap EPIRUS Biopharmaceuticals, Inc. (NASDAQ:EPRS)Wall Street Hints and NewsIn recent session activity, EPIRUS Biopharmaceuticals, Inc. (NASDAQ:EPRS) shares have traded +6.588%. Monitoring the stock price relative to moving averages may provide enhanced perspective on share performance. After a recent check, the stock has ...and more »
05/26/16 01:53 PMShares Poised for a Bounceback: EPIRUS Biopharmaceuticals, Inc. (NASDAQ:EPRS) - Wall Street Hints and News - Shares Poised for a Bounceback: EPIRUS Biopharmaceuticals, Inc. (NASDAQ:EPRS)Wall Street Hints and NewsMany investors are considering shares of EPIRUS Biopharmaceuticals, Inc. (NASDAQ:EPRS) to be “oversold” as the commodity reached $0.58 on a recent tick. An oversold stock has a current price that an investor thinks is lower than the inherent value of ...and more »
05/26/16 01:53 PMStock's Overselling Recap: Epirus Biopharmaceuticals Inc (NASDAQ:EPRS) - The Point Review - The Point ReviewStock's Overselling Recap: Epirus Biopharmaceuticals Inc (NASDAQ:EPRS)The Point ReviewEpirus Biopharmaceuticals Inc (NASDAQ:EPRS) has an ABR 2.50 which is the combined stock view of 4 analysts' poll results. As per the Zacks simplified descending rating scale, the ABR rank is displayed in the range of 1 to 5 where 1 represents a Strong ...Updated Trading Report: EPIRUS Biopharmaceuticals, Inc. (NASDAQ:EPRS) , Insmed, Inc. (NASDAQ:INSM)Street Updatesall 2 news articles »
05/26/16 10:11 AMThese 5 Stocks Under $10 Are About to Soar Higher -
05/18/16 09:27 PMETF’s with exposure to EPIRUS Biopharmaceuticals, Inc. : May 19, 2016 -
05/17/16 11:40 AMEPIRUS Biopharmaceuticals, Inc. :EPRS-US: Earnings Analysis: Q1, 2016 By the Numbers -
05/16/16 05:33 AMEpirus Biopharma downgraded by Leerink Partners -
05/12/16 02:36 AM[$$] New Epirus Model Sacrifices Clarity -
05/11/16 01:45 PMEpirus exec sees promise for biosimilars despite setback for company -
05/10/16 04:51 PMEPIRUS BIOPHARMACEUTICALS, INC. Files SEC form 10-Q, Quarterly Report -
05/10/16 10:26 AMBoston drug firm's shares slump due to job cuts, cash shortage -
05/09/16 04:20 PMEPIRUS BIOPHARMACEUTICALS, INC. Files SEC form 8-K, Costs Associated with Exit or Disposal Activities, Change in Dire -
05/09/16 03:18 PMEPIRUS Announces Reprioritization of Pipeline to Solely Focus on Biosimilars to Treat Rare Diseases and Key Leadership Changes - [at noodls] - New strategy to focus exclusively on BOW080 (eculizumab biosimilar) and BOW070 (tocilizumab biosimilar) in rare diseases with a combined target market opportunity of close to $6 billion of innovator sales ...
04/04/16 11:47 AMEdited Transcript of EPRS earnings conference call or presentation 15-Mar-16 12:00pm GMT -
03/29/16 05:10 AMEPIRUS BIOPHARMACEUTICALS, INC. Files SEC form 10-K, Annual Report -
03/15/16 01:38 PMCan EPIRUS Biopharmaceuticals, Inc. (NASDAQ:EPRS) Earnings Impress Markets? - Stocks Daily - Can EPIRUS Biopharmaceuticals, Inc. (NASDAQ:EPRS) Earnings Impress Markets?Stocks DailyAs per Zacks, the way to profitable investment is to invest in stocks from the leading industries. When stockholders acknowledge the real importance of earnings estimate review, they plan to follow the ratings to discover the best stocks. Lately, Zacks ...and more »
03/15/16 07:00 AMEPIRUS Biopharmaceuticals Inc Earnings Call scheduled for 8:00 am ET today -
03/15/16 06:07 AMQ4 2015 EPIRUS Biopharmaceuticals Inc Earnings Release - Before Market Open -
03/15/16 05:31 AMEPIRUS BIOPHARMACEUTICALS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statemen -
03/15/16 05:21 AMEpirus reports 4Q loss -
03/15/16 05:00 AMEPIRUS Biopharmaceuticals Reports Fourth Quarter and Fiscal Year 2015 Financial Results and Provides Business Update - [GlobeNewswire] - BOSTON, March 15, 2016-- EPIRUS Biopharmaceuticals, Inc., a pure-play biosimilar company focused on the global development and commercialization of biosimilar monoclonal antibodies, today reported financial ...
03/01/16 07:00 AMEPIRUS Biopharmaceuticals to Release Fourth Quarter and Fiscal Year 2015 Financial Results and Provide Business Update - [GlobeNewswire] - BOSTON, March 01, 2016-- EPIRUS Biopharmaceuticals, Inc., a pure-play biosimilar company focused on the development and commercialization of biosimilar monoclonal antibodies, today announced it will release ...
03/01/16 05:11 AMEPIRUS BIOPHARMACEUTICALS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements -
02/18/16 01:42 PMEpirus Biopharmaceuticals Inc Can't Be More Safe. Trades Significantly Higher - Sonoran Weekly Review - Epirus Biopharmaceuticals Inc Can't Be More Safe. Trades Significantly HigherSonoran Weekly ReviewThe stock of Epirus Biopharmaceuticals Inc (NASDAQ:EPRS) is a huge mover today! The stock is up 11.11% or $0.3 after the news, hitting $3 per share. About 55,313 shares traded hands. Epirus Biopharmaceuticals Inc (NASDAQ:EPRS) has declined ...
02/14/16 11:56 AMEpirus Biopharmaceuticals Incorporated (NASDAQ:EPRS) Shorted Shares Increased By 7.4% - fdanewsalert.com - Epirus Biopharmaceuticals Incorporated (NASDAQ:EPRS) Shorted Shares Increased By 7.4%fdanewsalert.comThe stock of Epirus Biopharmaceuticals Incorporated (NASDAQ:EPRS) registered an increase of 7.4% in short interest. EPRS's total short interest was 864,600 shares in February as published by FINRA. Its up 7.4% from 805,000 shares, reported previously.
02/11/16 12:55 PMLatest Analysts Reports On EPIRUS Biopharmaceuticals, Inc. (EPRS) - Risers & Fallers - Latest Analysts Reports On EPIRUS Biopharmaceuticals, Inc. (EPRS)Risers & FallersRecently stock market analysts have updated their consensus ratings on shares of EPIRUS Biopharmaceuticals, Inc. (EPRS). The latest broker reports which have been released state 3 analysts have a rating of “buy”, 1 analysts “outperform”, 0 analysts ...and more »
02/10/16 12:57 PMEPIRUS Biopharma (EPRS) Commences BOW015 Phase 3 in RA - EPIRUS Biopharmaceuticals, Inc. (Nasdaq: EPRS) announced the initiation of its global registration study for BOW015 (infliximab, reference biologic Remicade®ii) in active Rheumatoid Arthritis (RA) patients. EPIRUS plans to enroll over 500 patients in the ...
02/09/16 12:25 PMEPIRUS Biopharma (EPRS) Commences BOW015 Phase 3 in RA - StreetInsider.com - Pharmaceutical ProcessingEPIRUS Biopharma (EPRS) Commences BOW015 Phase 3 in RAStreetInsider.comEPIRUS Biopharmaceuticals, Inc. (Nasdaq: EPRS) announced the initiation of its global registration study for BOW015 (infliximab, reference biologic Remicade®ii) in active Rheumatoid Arthritis (RA) patients. EPIRUS plans to enroll over 500 patients in ...Epirus Biopharmaceuticals Incorporated (NASDAQ:EPRS) Short Interest Increased By 6.24%fdanewsalert.comEpirus Biopharmaceuticals Inc's Stock Is Sell After Forming Wedge DownSonoran Weekly ReviewEPIRUS Biopharmaceuticals Initiates Pivotal Global Phase 3 Clinical Study for BOW015 ...CNNMoneySeeking Alphaall 11 news articles »
02/09/16 06:32 AMEPIRUS BIOPHARMACEUTICALS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits -
02/09/16 06:04 AM7:04 am Epirus Biopharma initiates its global registration study for BOW015 in active Rheumatoid Arthritis patients -
02/09/16 06:00 AMEPIRUS Biopharmaceuticals Initiates Pivotal Global Phase 3 Clinical Study for BOW015 (Infliximab Biosimilar) - [GlobeNewswire] - UNIFORM i Study builds on prior successful Phase 1 and Phase 3 studies Intended to support harmonized global filing for BOW015 in 2017 BOW015 is a biosimilar for Remicade ®, which had global sales of $8.8 ...
02/05/16 03:01 PMEPIRUS Biopharmaceuticals to Participate in Bloomberg Intelligence Healthcare Event on February 12 - [GlobeNewswire] - BOSTON, Feb. 05, 2016-- EPIRUS Biopharmaceuticals, Inc., a biosimilar company focused on the global development and commercialization of biosimilar monoclonal antibodies, today announced it will participate ...
02/05/16 12:03 PMSentiment And Earnings Update For EPIRUS Biopharmaceuticals, Inc. (NASDAQ:EPRS) - Investor Newswire - Sentiment And Earnings Update For EPIRUS Biopharmaceuticals, Inc. (NASDAQ:EPRS)Investor NewswireZacks Research, combined analysts opinion on EPIRUS Biopharmaceuticals, Inc. (NASDAQ:EPRS) and gave an average broker rating of 1. The research firm rating mechanism takes into account the research firms' forecasts on a one to five scale. As per the ...and more »
02/05/16 12:03 PMEPIRUS Biopharmaceuticals, Inc. (NASDAQ:EPRS): Stock in the spotlight - Stocks Daily - EPIRUS Biopharmaceuticals, Inc. (NASDAQ:EPRS): Stock in the spotlightStocks DailyEPIRUS Biopharmaceuticals, Inc. (NASDAQ:EPRS) has successfully managed to attain positive rating on its stock. Zacks planned a poll of sell-side experts after which the firm assigned 1 rating on company's stock. This consensus rating, which is placed ...
About Epirus Biopharmaceuticals

Epirus Biopharmaceuticals logoEPIRUS Biopharmaceuticals, Inc. (Epirus) is a commercial-stage biopharmaceutical company. The Company is engaged in developing, manufacturing, and commercializing biosimilar therapeutics (biosimilars). The Company has a pipeline of operationally synergistic monoclonal antibodies (MAbs) in inflammation and immunology. The Company's lead product candidate, BOW015 is indicated for the treatment of various inflammatory diseases. The Company has launched BOW015 under the brand name, Infimab. The Company's products include BOW015, which contains infliximab; BOW050, which contains adalimumab; BOW070, which contains tocilizumab; BOW080, which contains eculizumab; BOW090, which contains ustekinumab, and BOW100, which contains golimumab.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: EPRS
  • CUSIP:
Key Metrics:
  • Previous Close: $0.52
  • 50 Day Moving Average: $0.75
  • 200 Day Moving Average: $2.39
  • P/E Ratio: N/A
  • P/E Growth: 0.11
  • Market Cap: $13.62M
  • Current Quarter EPS Consensus Estimate: $-0.96 EPS
Additional Links:
Epirus Biopharmaceuticals (NASDAQ:EPRS) Chart for Monday, June, 27, 2016


            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha